Drugs to Prevent and Treat Venous Thromboembolic Disease During Pregnancy.

Andra H James, Jerome J Federspiel

Abstract readReview

In one paragraph

Review in Clinics in perinatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Andra H JamesDivision of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Duke University School of Medicine, Durham, NC, USA; Division of Hematology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA.

Jerome J FederspielDivision of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Duke University School of Medicine, Durham, NC, USA; Division of Hematology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. Electronic address: Jerome.federspiel@duke.edu.

Funding

Duke Women's Reproductive Health Research ScholarsK12HD103083 · NICHD · DUKE UNIVERSITY · PI Cindy Amundsen · 2020 to 2026

$2.2M

NICHD NIH HHS K12 HD103083

6 · The paper itself

Abstract

The use of agents to prevent and treat thromboembolism in pregnancy continues to increase, likely a reflection of greater burden of comorbid conditions in pregnant people, increased awareness of venous thromboembolism prevention efforts, and enhanced access to diagnostic testing. For this reason, obstetricians commonly find themselves involved in the management of patients who are receiving anticoagulation during pregnancy. Here, we summarize the features of anticoagulants used in pregnancy. Despite the advent of newer agents, the most common anticoagulant used in pregnancy remains heparin derivatives (primarily the low-molecular-weight forms).

Indexed as

AnticoagulantsPregnancy Complications, CardiovascularVenous ThromboembolismAntithrombinsDabigatranFemaleFondaparinuxHeparinHeparin, Low-Molecular-WeightHumansPolysaccharidesPregnancyWarfarinAnticoagulantsAntithrombinsDabigatranFondaparinuxHeparinHeparin, Low-Molecular-WeightPolysaccharidesWarfarinDirect oral anticoagulantDirect thrombin inhibitorFactor XI inhibitorFondaparinuxHeparinPregnancyWarfarin low-molecular-weight heparin

Identifiers

PMID42556980

DOI10.1016/j.clp.2026.05.001

PMCPMC13449145

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.